Profile data is unavailable for this security.
About the company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
- Revenue in USD (TTM)4.49m
- Net income in USD-10.97m
- Incorporated2017
- Employees7.00
- LocationEnsysce Biosciences Inc7946 Ivanhoe Avenue, Suite 201LA JOLLA 92037United StatesUSA
- Phone+1 (858) 263-4196
- Fax+1 (302) 636-5454
- Websitehttps://ensysce.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Halberd Corp | 281.24k | 25.34k | 1.13m | 3.00 | 0.6897 | -- | 44.61 | 4.02 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Pharmagreen Biotech Inc | 3.01k | -226.26k | 1.26m | 0.00 | -- | -- | 2.28 | 418.91 | -0.0003 | -0.0003 | 0.00 | -0.0035 | 0.0286 | 0.2026 | 0.0669 | -- | -214.92 | -709.50 | -- | -- | 44.85 | -- | -7,518.27 | -147,637.60 | 0.0375 | -- | -- | -- | 13.67 | -- | -76.59 | -- | -- | -- |
| Exousia Pro Inc | 0.00 | -854.02k | 1.35m | 0.00 | -- | -- | -- | -- | -0.0642 | -0.0642 | 0.00 | -0.0318 | 0.00 | -- | -- | -- | -1,313,877.00 | -- | -- | -- | -- | -- | -- | -- | -- | -1,816.06 | -- | -- | -- | -- | -248.31 | -- | -- | -- |
| International Stem Cell Corp | 9.39m | -149.00k | 1.40m | 32.00 | -- | -- | 8.70 | 0.1492 | -0.0187 | -0.0187 | 1.17 | 0.0655 | 1.80 | 2.66 | 11.08 | 293,468.80 | -1.13 | -16.11 | -10.84 | -52.88 | 57.86 | 59.53 | -0.6283 | -10.91 | 0.4604 | 0.6258 | 0.8632 | -- | 16.64 | -0.8308 | -59.54 | -- | -19.12 | -- |
| GlucoTrack Inc | 0.00 | -25.85m | 1.50m | 11.00 | -- | 0.5395 | -- | -- | -1,225.32 | -1,225.32 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -567.22 | -147.48 | -- | -192.87 | -- | -- | -- | -- | -- | -3.51 | 0.5422 | -- | -- | -- | -218.40 | -- | 34.73 | -- |
| Virax Biolabs Group Ltd | 2.99k | -5.64m | 1.53m | 19.00 | -- | 0.2545 | -- | 512.94 | -1.25 | -1.25 | 0.0007 | 0.8118 | 0.0004 | 0.5382 | 1.94 | 157.37 | -74.60 | -111.16 | -77.64 | -133.38 | -1,515.05 | -4.50 | -189,095.00 | -7,009.42 | 11.21 | -92.32 | 0.0959 | -- | -95.95 | -42.40 | 9.98 | -- | -- | -- |
| Ensysce Biosciences Inc | 4.49m | -10.97m | 1.54m | 7.00 | -- | 1.15 | -- | 0.3432 | -6.36 | -6.36 | 2.32 | 0.3783 | 0.7144 | -- | 5.02 | 641,138.60 | -174.67 | -48.70 | -270.43 | -62.66 | -- | -- | -244.49 | -501.34 | -- | -457.15 | 0.3071 | -- | 133.58 | -- | 24.83 | -- | -- | -- |
| Carisma Therapeutics Inc | 52.63m | 8.04m | 1.61m | 46.00 | 0.2047 | -- | 0.1687 | 0.0306 | 0.1881 | 0.1881 | 1.26 | -0.0208 | 2.17 | -- | -- | 1,144,174.00 | 33.09 | -26.58 | 51.48 | -30.35 | -- | -- | 15.28 | -169.12 | -- | -- | -- | -- | 31.59 | -- | 30.39 | -- | -1.99 | -- |
| Galera Therapeutics Inc | 0.00 | -8.99m | 1.66m | 3.00 | -- | -- | -- | -- | -0.1302 | -0.1302 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -129.27 | -96.94 | -145.04 | -116.42 | -- | -- | -- | -- | -- | -- | 34.30 | -- | -- | -- | 67.91 | -- | -- | -- |
| Clearmind Medicine Inc | 0.00 | -3.86m | 1.68m | -- | -- | 0.1485 | -- | -- | -30.64 | -30.64 | 0.00 | 7.54 | 0.00 | -- | -- | -- | -57.83 | -128.70 | -178.71 | -360.04 | -- | -- | -- | -- | -- | -- | 0.5987 | -- | -- | -- | 26.60 | -- | -- | -- |
| Agentix Corp | 0.00 | -655.59k | 1.68m | -- | -- | -- | -- | -- | -0.0164 | -0.0164 | 0.00 | -0.0853 | 0.00 | -- | -- | -- | -746.86 | -- | -- | -- | -- | -- | -- | -- | -- | -7.07 | -- | -- | -- | -- | 3.09 | -- | -- | -- |
| Hcw Biologics Inc | 422.03k | -22.21m | 1.76m | 36.00 | -- | -- | -- | 4.16 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 1.83m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 1.89m | 7.00 | -- | 0.2963 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.96m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Ensysce Biosciences Inc's reporting currency: US Dollar USD
11.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 98.48k | 2.71% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 86.67k | 2.39% |
| Adage Capital Management LPas of 30 Sep 2025 | 74.71k | 2.06% |
| HRT Financial LPas of 31 Dec 2025 | 24.49k | 0.67% |
| Financial Plan, Inc.as of 31 Dec 2025 | 24.00k | 0.66% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 23.85k | 0.66% |
| Geode Capital Management LLCas of 31 Dec 2025 | 22.09k | 0.61% |
| Williams & Novak LLCas of 31 Dec 2025 | 17.85k | 0.49% |
| Citadel Securities LLCas of 30 Sep 2025 | 14.52k | 0.40% |
| Virtu Americas LLCas of 30 Sep 2025 | 14.22k | 0.39% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
